Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs

NCT07589322 · Recruiting

Last updated 2026-05-28

This clinical trial is testing how two diabetes medications affect weight loss in adults with obesity and metabolic syndrome over a 6-month period.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 120 people Planned (estimated).

Who can join Ages 20–65 · all sexes

Timeline Started 2026-03 · est. completion 2029-09

Where 1 site · Taiwan

What this study is testing ClinicalTrials.gov NCT07589322 ↗

Description as written by the study sponsor.

This randomized, open label, head to head clinical trial directly compares tirzepatide and semaglutide in adults with obesity and metabolic syndrome (N=120, age 20-65, 1:1 randomization). Participants undergo deep phenotyping at baseline, 6 months, and 12 months, including DXA (regional fat, lean mass, and BMD), MRI PDFF (liver fat), 7 site skinfold thickness, grip strength, fasting biochemistry, and AI processed 12 lead ECGs. Centralized biobanking of serum, plasma, and PBMCs enables targeted and discovery multi omic analyses.

Treatments tested

Tirzepatide with lifestyle modification Drug

Starting at Tirzepatide 2.5 mg weekly and escalated as tolerated to 10 mg along with standardized lifestyle counseling by a dietitian (caloric deficit, physical activity guidance) and written materials.
Semaglutide with lifestyle modification Drug

Starting at Semaglutide 0.25 mg weekly and escalated as tolerated to 2.4 mg along with standardized lifestyle counseling by a dietitian (caloric deficit, physical activity guidance) and written materials.

Main thing measured	Percent change in total body weight from baseline to 6 months.
Sponsor	Tri-Service General Hospital
Conditions studied	Obesity and Metabolic Syndrome
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07589322 ↗